Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11

Belantamab mafodotin, a B-cell maturation antigen-targeting antibody–drug conjugate (ADC), was investigated in Japanese patients with relapsed/refractory multiple myeloma in Part 1 of the phase I DREAMM-11 study. Patients who had received ≥ 2 prior lines of therapy including a proteasome inhibitor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Shinsuke, Sunami, Kazutaka, Mishima, Yuko, Fujii, Taku, Kato, Hitomi, Terao, Takumi, Matsuzawa, Yuki, Matsubara, Mari, Crossman, Timothy, Kremer, Brandon E., Gupta, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615937/
https://www.ncbi.nlm.nih.gov/pubmed/37668832
http://dx.doi.org/10.1007/s12185-023-03652-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615937/
https://www.ncbi.nlm.nih.gov/pubmed/37668832
http://dx.doi.org/10.1007/s12185-023-03652-5

Ejemplares similares